- Home
- ONCO vs ISPC Comparison
ONCO vs ISPC Comparison
Compare ONCO & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCO | ISPC |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 1.9M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ONCO | ISPC |
|---|---|---|
| Price | $1.85 | $0.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.1M | ★ 9.4M |
| Earning Date | 11-13-2025 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $815,371.00 | ★ $9,291,115.00 |
| Revenue This Year | N/A | $35.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.05 | $0.14 |
| 52 Week High | $7.65 | $2.16 |
Technical Indicators
Market Signals| Indicator | ONCO | ISPC |
|---|---|---|
| Relative Strength Index (RSI) | 58.22 | 35.60 |
| Support Level | $0.51 | N/A |
| Resistance Level | $2.01 | $0.44 |
| Average True Range (ATR) | 0.66 | 0.04 |
| MACD | 0.13 | -0.00 |
| Stochastic Oscillator | 22.27 | 4.74 |
Price Performance
Historical ComparisonAbout ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.